Ultra-Hypofractionated vs. Moderately Hypofractionated Proton Therapy for Early Breast Cancer After Lumpectomy

Breast-conserving surgery (BCS) followed by whole-breast irradiation (WBI) remains the standard therapeutic approach for early-stage breast cancer. Long-term follow-up data from the FAST trial (10-year analysis) demonstrated that the 28.5 Gy/5-fraction regimen exhibited comparable adverse effects to the conventional 50 Gy/25-fraction regimen, with no statistically significant differences in photographic cosmetic assessments at 2 and 5 years post-treatment. The FAST-Forward trial demonstrated comparable 5-year ipsilateral breast tumor recurrence rates (IBTR) and incidence of radiation-related t

Trial Details

NCT ID
NCT07135661
Phase
NA
Sponsor
Shanghai Proton and Heavy Ion Center
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • moderate hypofractionated proton radiotherapy
  • ultra-hypofractionated proton radiotherapy
Locations (sample)
  • Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

  • Age ≥ 40 years
  • Pathologically (cytologically or histologically) confirmed unilateral primary invasive breast carcinoma
  • Breast conserving surgery + sentinel lymph node biopsy/axillary lymph node dissection, pathological stage pT1-2N0M0,negative margins (≥ 2 mm)
  • No distant metastasis confirmed by CT, MRI, bone scan, and PET/CT

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →